THE effect of increased intra-abdominal pressure due to ascites upon portal and systemic hemodynamics has not been directly documented although the hemodynamics of ascitic cirrhotic patients have ...

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious ...

More information: Nicolò Brandi et al, Liver Lesions at Risk of Transformation into Hepatocellular Carcinoma in Cirrhotic ...

ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated steatohepatitis (MASH) continue to ...

A combination of NfL, GFAP, tau, and UCHL1 was effective in diagnosing MHE in all cirrhotic patients (area under the receiver operating characteristic curve [hereinafter referred to as AUROC]: 0. ...

We made significant strides in 2024 and the first quarter of 2025 to complete our Phase 2b studies of EFX and advance our Phase 3 SYNCHRONY ...